Prostate Cancer Devices Market Size, Share, Growth, and Industry Analysis, By Type (Robotic Surgery Devices, EBRT Devices, HIFU Devices, Brachytherapy, and Cryotherapy Devices), By Application (Hospitals and Ambulatory Surgical Centers), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

PROSTATE CANCER DEVICES MARKET OVERVIEW

The global Prostate Cancer Devices Market is starting at an estimated value of USD 5.22 Billion in 2026, ultimately reaching USD 14.36 Billion by 2035. This growth reflects a steady CAGR of 11.9% from 2026 through 2035.

The Prostate Cancer Devices Market is expanding due to increasing prostate cancer prevalence and growing adoption of advanced treatment technologies such as robotic surgery systems, radiation therapy equipment, cryotherapy devices, and high-intensity focused ultrasound (HIFU) systems. Globally, prostate cancer represents nearly 14% of all male cancer diagnoses, with more than 1.4 million new cases identified annually. Medical technology innovation has increased treatment accuracy, and robotic surgical platforms are now used in approximately 65% of prostatectomy procedures worldwide. In addition, radiation therapy devices such as external beam radiation therapy (EBRT) systems are utilized in nearly 50% of prostate cancer treatment plans. The Prostate Cancer Devices Market Analysis highlights that more than 8,000 hospitals globally use advanced prostate cancer treatment technologies, strengthening the Prostate Cancer Devices Market Growth across healthcare institutions.

The United States dominates the Prostate Cancer Devices Market Outlook, driven by strong healthcare infrastructure and high prostate cancer screening rates. Approximately 1 in 8 men in the United States are diagnosed with prostate cancer during their lifetime, with more than 280,000 new cases reported annually. Robotic-assisted surgery is widely adopted, with nearly 85% of prostatectomy procedures performed using robotic surgical systems. The country also operates more than 2,500 radiation therapy centers, many equipped with EBRT systems specifically designed for prostate cancer treatment. In addition, over 1,200 hospitals use advanced brachytherapy technologies for localized prostate cancer therapy. The Prostate Cancer Devices Market Research Report indicates that nearly 70% of urology departments in major U.S. hospitals utilize multiple prostate cancer treatment technologies, strengthening the national medical device ecosystem.

Key Findings

LATEST TRENDS

Growing Adoption of Robotic Prostatectomy to Boost Market Trend

The Prostate Cancer Devices Market Trends indicate increasing adoption of minimally invasive treatment technologies and advanced surgical robotics. Robotic-assisted prostate surgery has significantly improved surgical precision, allowing surgeons to perform procedures with nearly 40% greater accuracy compared with traditional surgical techniques. Today, more than 6,500 robotic surgical systems are installed globally, with a large percentage used in urological procedures. Another key trend in the Prostate Cancer Devices Market Research Report is the rapid adoption of advanced radiation therapy technologies. External beam radiation therapy (EBRT) systems are used in nearly 50% of prostate cancer treatment plans, offering precise radiation delivery that reduces damage to surrounding tissues by nearly 30% compared with older radiotherapy methods.

High-intensity focused ultrasound (HIFU) technologies are also gaining traction. Clinical studies show that HIFU treatments can destroy prostate cancer tissue with precision rates exceeding 85% in localized tumor treatments. In addition, cryotherapy devices capable of freezing cancer cells at temperatures below −40°C are used in approximately 12% of localized prostate cancer cases. Healthcare providers are also integrating AI-based treatment planning software into radiation therapy systems. Nearly 37% of radiation oncology centers worldwide now use automated treatment planning tools to improve therapy accuracy and reduce treatment planning time by nearly 25%.

Download Free Sample to learn more about this report

PROSTATE CANCER DEVICES MARKET SEGMENTATION

By Type

Based on type, the market is classified into robotic surgery devices, EBRT devices, HIFU devices, cryotherphy devices, and brachytherapy.

• Robotic Surgery Devices: Robotic surgery devices represent the leading segment in the Prostate Cancer Devices Market, accounting for nearly 35% of prostate cancer treatment technologies used globally. Robotic-assisted prostatectomy procedures have increased significantly, with approximately 65% of prostate surgeries performed using robotic systems in developed healthcare systems. More than 6,500 robotic surgical platforms are installed worldwide, and nearly 70% of them are used in urology and prostate cancer procedures. These systems provide 10× magnified 3D visualization and improved surgical precision, reducing blood loss by nearly 20% during procedures. Hospitals adopting robotic surgery technologies report 30% shorter patient recovery times compared with traditional open surgery. In addition, robotic systems allow surgeons to perform complex procedures through small incisions, improving surgical accuracy and reducing complication rates by nearly 15%. As a result, robotic surgery devices continue to expand their presence in the Prostate Cancer Devices Market Analysis.

• EBRT Devices: External Beam Radiation Therapy (EBRT) devices account for approximately 30% of prostate cancer treatment technologies globally. These devices are widely used in radiation oncology centers to deliver targeted radiation doses to prostate tumors while minimizing damage to surrounding tissues. Nearly 50% of prostate cancer patients receive EBRT as part of their treatment plan, particularly in cases of localized or advanced cancer stages. Modern EBRT systems use advanced imaging technologies that improve radiation targeting accuracy by nearly 25% compared with older radiotherapy equipment. Globally, more than 10,000 radiation therapy systems are installed across hospitals and oncology centers. These devices are capable of delivering high-energy radiation beams capable of destroying cancer cells while protecting healthy tissues. Additionally, improvements in intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) technologies have increased treatment success rates by nearly 20% in localized prostate cancer cases.

• Brachytherapy: Brachytherapy devices contribute approximately 18% of prostate cancer treatment technologies and are widely used for localized prostate cancer treatment. The procedure involves placing small radioactive seeds directly inside the prostate gland, allowing radiation to target cancer cells with minimal exposure to surrounding tissues. Clinical data indicates that brachytherapy treatment success rates reach nearly 85% for early-stage prostate cancer patients. Hospitals worldwide perform more than 60,000 brachytherapy procedures annually for prostate cancer treatment. The technology allows continuous radiation delivery over several weeks, improving treatment effectiveness while reducing side effects. Brachytherapy also shortens hospital stays, with most procedures completed within 24 hours. Additionally, advancements in imaging technologies have improved radioactive seed placement accuracy by nearly 30%, enhancing treatment precision. These factors continue to support the adoption of brachytherapy devices in the Prostate Cancer Devices Market Outlook.

• HIFU Devices: High-Intensity Focused Ultrasound (HIFU) devices represent approximately 10% of prostate cancer treatment technologies worldwide. HIFU systems use focused ultrasound energy to heat and destroy cancerous prostate tissue without requiring surgical incisions. Clinical studies show that HIFU treatment can destroy cancer cells with success rates reaching 80% to 90% for localized prostate tumors. The technology operates by delivering ultrasound waves that raise tissue temperatures above 60°C, effectively destroying malignant cells. HIFU procedures are typically completed within 1 to 3 hours, making them less invasive compared with traditional surgery. Around 150 specialized medical centers globally currently offer HIFU treatment for prostate cancer. Additionally, HIFU technology reduces hospital stays by nearly 40% compared with conventional prostatectomy procedures. As minimally invasive therapies become more popular, HIFU devices are gaining importance in the Prostate Cancer Devices Market Research Report.

• Cryotherapy Devices: Cryotherapy devices account for approximately 7% of prostate cancer treatment technologies, primarily used for treating localized prostate cancer or recurrent tumors after radiation therapy. Cryotherapy works by freezing cancer cells using extremely low temperatures below −40°C, which destroys malignant tissue within the prostate gland. Clinical studies indicate that cryotherapy treatments achieve tumor destruction rates of nearly 75% in early-stage prostate cancer patients. Globally, more than 20,000 cryotherapy procedures are performed annually for prostate cancer treatment. The procedure is minimally invasive and typically requires only 1 to 2 days of hospital recovery time. Cryotherapy devices also allow physicians to monitor freezing zones through real-time imaging technologies, improving treatment accuracy by nearly 20%. Increasing adoption of minimally invasive oncology treatments continues to support the growth of cryotherapy technologies within the Prostate Cancer Devices Market Industry Analysis.

By Application

On the basis of application, the market is divided into ambulatory surgical centers and hospitals.  

• Hospitals: Hospitals represent the largest application segment in the Prostate Cancer Devices Market, accounting for nearly 75% of prostate cancer treatment procedures globally. Large hospitals and specialized oncology centers possess advanced medical infrastructure required for robotic surgery systems, radiation therapy devices, and brachytherapy equipment. Globally, more than 8,000 hospitals provide prostate cancer treatment services, and approximately 65% of prostatectomy surgeries are performed in hospital operating rooms using robotic surgical systems. Hospitals also operate the majority of radiation therapy centers, with nearly 70% of external beam radiation therapy (EBRT) devices installed in hospital oncology departments. In addition, hospitals conduct more than 60,000 brachytherapy procedures annually for prostate cancer treatment. These institutions have access to multidisciplinary cancer treatment teams, including oncologists, radiologists, and urologists, which improves treatment success rates by nearly 20% compared with smaller healthcare facilities. Due to strong infrastructure and specialized staff, hospitals remain the dominant segment in the Prostate Cancer Devices Market Analysis.

• Ambulatory Surgical Centers: Ambulatory Surgical Centers (ASCs) account for approximately 25% of prostate cancer treatment procedures, particularly for minimally invasive therapies such as cryotherapy and high-intensity focused ultrasound (HIFU). Globally, there are more than 12,000 ambulatory surgical centers, many of which specialize in outpatient surgical procedures. These facilities offer shorter treatment times and reduced hospital stays, allowing patients to return home within 24 hours after certain prostate cancer procedures. Minimally invasive treatments performed in ASCs reduce patient recovery times by nearly 30% compared with traditional inpatient procedures. Approximately 35% of cryotherapy procedures for prostate cancer are performed in ambulatory surgical centers due to their lower operational costs and efficient outpatient care models. In addition, ASCs help reduce healthcare system burdens by increasing treatment capacity for early-stage prostate cancer patients. As demand for cost-effective and outpatient cancer treatment grows, ambulatory surgical centers continue to expand their role in the Prostate Cancer Devices Market Outlook.

MARKET DYNAMICS

Driving Factor

Increasing global prevalence of prostate cancer

The primary driver of the Prostate Cancer Devices Market Growth is the increasing number of prostate cancer diagnoses worldwide. Global healthcare statistics indicate that more than 1.4 million men are diagnosed with prostate cancer annually, representing approximately 14% of all male cancer cases. Early detection programs have expanded significantly, with nearly 65% of men over the age of 55 undergoing prostate cancer screening tests in developed countries. Advancements in treatment technologies are also accelerating market demand. Robotic surgery devices provide enhanced surgical precision and reduce patient recovery times by nearly 30% compared with conventional surgical procedures. In addition, radiation therapy technologies such as EBRT allow doctors to deliver targeted radiation doses while minimizing exposure to healthy tissues.

Restraining Factor

High cost of advanced medical devices

One major restraint affecting the Prostate Cancer Devices Market Forecast is the high cost associated with advanced medical technologies such as robotic surgery systems and radiation therapy equipment. Robotic surgical systems require specialized infrastructure and training, and approximately 42% of hospitals report budget limitations preventing equipment purchases. In addition, radiation therapy equipment installation requires dedicated oncology facilities and shielding infrastructure. Nearly 35% of hospitals in developing countries lack access to advanced radiation therapy equipment. Maintenance costs also contribute to financial barriers, as robotic surgical systems require annual servicing and specialized technical support. These factors limit the adoption of advanced prostate cancer treatment technologies in some healthcare systems.

Expansion of minimally invasive treatment technologies

Opportunity

The Prostate Cancer Devices Market Opportunities are expanding with the increasing popularity of minimally invasive treatment technologies. Robotic surgery systems allow surgeons to perform prostate cancer procedures through small incisions, reducing patient recovery times by nearly 35% compared with open surgical procedures. Similarly, HIFU devices provide non-invasive tumor destruction by focusing ultrasound energy directly on cancerous tissue. Clinical trials show that HIFU treatments achieve successful tumor ablation in approximately 80% to 90% of localized prostate cancer cases. Advancements in imaging technologies are also supporting this opportunity.

Limited access to specialized oncology infrastructure

Challenge

A significant challenge in the Prostate Cancer Devices Market Outlook is the limited availability of specialized oncology infrastructure in developing regions. Currently, more than 50% of low-income countries operate fewer than 1 radiation therapy machine per million people. In addition, robotic surgery systems require specialized surgeon training programs. Approximately 28% of hospitals report shortages of trained robotic surgery specialists, which limits the ability to expand minimally invasive prostate cancer treatments. These infrastructure limitations create disparities in access to advanced prostate cancer treatment technologies worldwide.

• Download Free Sample to learn more about this report

•  

PROSTATE CANCER DEVICES MARKET REGIONAL INSIGHTS

• North America

North America holds the largest share of the Prostate Cancer Devices Market, accounting for nearly 42% of global installations of prostate cancer diagnostic and treatment devices. The region records more than 280,000 new prostate cancer cases annually in the United States alone, representing approximately 27% of all male cancer diagnoses. More than 2,500 hospitals and specialized cancer centers across the U.S. and Canada utilize advanced prostate cancer devices such as biopsy systems, radiation therapy equipment, and robotic surgical platforms. Screening adoption is high, with nearly 65% of men above age 55 undergoing PSA testing or related diagnostic procedures. The region also hosts over 60% of robotic-assisted prostatectomy procedures, with more than 1,700 robotic surgical systems installed in hospitals. Increasing adoption of MRI-guided biopsy devices and high-intensity focused ultrasound systems is further strengthening device demand.

• Europe

Europe represents approximately 28% of the global Prostate Cancer Devices Market share, supported by strong healthcare infrastructure and early cancer screening programs. The region reports nearly 470,000 prostate cancer diagnoses annually, making it one of the most common cancers among men in Europe. Countries such as Germany, the United Kingdom, France, and Italy collectively operate more than 1,200 oncology centers equipped with advanced diagnostic imaging systems and radiation therapy equipment. Over 55% of prostate cancer surgeries in Western Europe are performed using minimally invasive or robotic-assisted procedures. The region has installed more than 900 radiotherapy systems used for prostate cancer treatment, including proton therapy and intensity-modulated radiation therapy systems. Government-funded screening initiatives and increasing adoption of MRI-targeted biopsy procedures continue to drive device utilization across Europe.

• Asia-Pacific​​​​​

Asia-Pacific accounts for nearly 22% of the Prostate Cancer Devices Market, driven by increasing cancer awareness, expanding healthcare infrastructure, and rising elderly male populations. The region reports more than 350,000 new prostate cancer cases annually, with Japan, China, India, and South Korea representing the largest patient populations. Japan alone diagnoses nearly 90,000 prostate cancer cases per year, while China reports over 120,000 new cases annually. More than 1,500 hospitals across Asia-Pacific are now equipped with prostate cancer diagnostic imaging systems such as MRI and ultrasound biopsy devices. Adoption of robotic-assisted prostatectomy is also increasing, with more than 400 robotic surgical systems installed across major hospitals in the region. Growing investments in oncology centers and screening programs for men aged 50 years and above are further expanding demand for prostate cancer treatment devices.

• Middle East & Africa

The Middle East & Africa region holds nearly 8% of the Prostate Cancer Devices Market, with demand driven by improving healthcare infrastructure and rising cancer screening awareness. The region records more than 75,000 new prostate cancer cases annually, with higher incidence rates observed in Gulf countries and South Africa. Countries such as Saudi Arabia, the UAE, and Qatar have invested heavily in advanced oncology facilities, with over 120 specialized cancer treatment centers operating across the region. Many of these facilities utilize advanced radiation therapy equipment and ultrasound-guided biopsy systems. Prostate cancer screening adoption is growing, with approximately 35% of men aged above 50 participating in screening programs in major urban healthcare systems. Increasing installation of modern radiotherapy devices and robotic surgical platforms is expected to strengthen device adoption in leading hospitals throughout the region.

LIST OF TOP PROSTATE CANCER DEVICES COMPANIES

• Intuitive Surgical
• Varian Medical Systems
• Elekta
• Accuray
• Bard Medical (BD)
• Eckert & Ziegler
• Healthtronics
• EDAP TMS
• SonaCare Medical
• Galil Medical (BTG)

Top Companies with Highest Market Share

• Intuitive Surgical: Approximately 55% of global robotic surgical system installations used in prostate surgery.
• Varian Medical Systems: Nearly 35% of radiation therapy systems used in prostate cancer treatment worldwide.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Prostate Cancer Devices Market is expanding due to the rising global burden of prostate cancer and increasing demand for advanced treatment technologies. Healthcare systems worldwide operate more than 10,000 radiation therapy centers and over 6,500 robotic surgical platforms, many of which are used for prostate cancer treatment. Hospitals continue to invest in new robotic surgery systems, with approximately 900 to 1,000 new robotic installations added annually across global healthcare facilities. Additionally, more than 150 medical device innovation projects are currently focused on improving prostate cancer treatment technologies such as robotic surgery platforms, precision radiation therapy devices, and ultrasound-based tumor ablation systems. Government cancer control programs in more than 60 countries also support investments in oncology infrastructure, increasing the adoption of advanced prostate cancer treatment devices.

Opportunities in the Prostate Cancer Devices Market Analysis are growing as healthcare providers expand early cancer detection and treatment capabilities. Screening programs targeting men above 55 years of age have increased significantly, with nearly 65% of men in developed healthcare systems undergoing prostate-specific antigen (PSA) testing. As a result, the number of early-stage prostate cancer diagnoses continues to rise, increasing the demand for minimally invasive treatment technologies. Medical device manufacturers are also exploring opportunities in emerging markets, where oncology infrastructure is expanding rapidly. Countries in Asia-Pacific and Latin America are establishing new oncology treatment centers, with more than 500 new cancer treatment facilities developed in the last decade. These infrastructure developments create strong investment potential for robotic surgery systems, radiation therapy devices, and advanced prostate cancer treatment equipment.

NEW PRODUCT DEVELOPMENT

New product development in the Prostate Cancer Devices Market focuses on improving treatment accuracy, reducing procedure times, and enhancing patient recovery outcomes. Robotic surgical systems continue to evolve with improved visualization technologies, including 10× magnified 3D imaging systems that allow surgeons to perform highly precise prostatectomy procedures. New robotic platforms are capable of improving surgical precision by nearly 20% compared with earlier-generation systems. These systems also integrate advanced motion control technologies that reduce surgical tremor and allow surgeons to perform complex procedures with improved accuracy. Currently, more than 70% of robotic surgery procedures in urology involve prostate cancer treatment, highlighting the importance of robotic innovation in this market segment.

Radiation therapy technologies are also undergoing rapid development within the Prostate Cancer Devices Market Research Report. Modern external beam radiation therapy systems now include image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), improving radiation targeting precision by nearly 30% compared with earlier radiotherapy systems. High-intensity focused ultrasound (HIFU) devices are another area of innovation, with new systems capable of delivering ultrasound energy at frequencies above 3 MHz, enabling effective destruction of prostate cancer tissue without surgical incisions. Cryotherapy technologies are also improving, with advanced temperature monitoring systems that maintain freezing temperatures below −40°C to ensure complete tumor destruction. These innovations are strengthening the technological ecosystem of the Prostate Cancer Devices Market Industry Analysis.

FIVE RECENT DEVELOPMENTS (2023–2025)

• In 2023, a robotic surgery manufacturer introduced a prostate surgery platform with 3D imaging resolution improved by 25%.
• In 2024, a radiation therapy device manufacturer developed AI-based treatment planning software reducing planning time by 30%.
• In 2025, a HIFU device was introduced capable of targeting tumors with sub-millimeter precision accuracy.
• In 2024, a cryotherapy system upgrade improved tumor freezing efficiency by 20%.
• In 2023, a brachytherapy system introduced automated seed placement technology improving treatment precision by 18%.

REPORT COVERAGE OF PROSTATE CANCER DEVICES MARKET

The Prostate Cancer Devices Market Report provides a comprehensive evaluation of medical technologies used in prostate cancer diagnosis and treatment. The report analyzes more than 1.4 million prostate cancer diagnoses reported annually worldwide, examining how treatment technologies such as robotic surgery systems, radiation therapy devices, cryotherapy equipment, and HIFU technologies are being adopted across global healthcare systems. It also evaluates prostate cancer treatment patterns across more than 8,000 hospitals and oncology centers, highlighting the increasing adoption of minimally invasive treatment technologies. The Prostate Cancer Devices Market Analysis further explores the role of advanced imaging technologies that allow physicians to detect prostate tumors with diagnostic accuracy rates exceeding 90%.

The report also includes detailed segmentation analysis by device type and healthcare application. Technologies analyzed include robotic surgery devices, external beam radiation therapy systems, brachytherapy equipment, HIFU devices, and cryotherapy systems. Additionally, the report evaluates application segments such as hospitals and ambulatory surgical centers, which together perform nearly 100% of prostate cancer treatment procedures worldwide. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, examining prostate cancer treatment infrastructure across more than 10,000 oncology treatment facilities. The Prostate Cancer Devices Market Outlook also highlights technological advancements, healthcare investments, and emerging treatment innovations that are shaping the global prostate cancer treatment device ecosystem.